Oral pharmaceutical dosage forms

Abstract

Controlled release oral dosage forms suitable for administration of methylphenidate are provided. Abuse-resistant controlled release oral dosage forms suitable for administration of methylphenidate are also provided. Methods of treating ADD and ADHD using the oral dosage forms are also provided.

1 .- 57 . (canceled) 
     
     
         58 . A formulation comprising:
 methylphenidate;   sucrose acetate isobutyrate (SAIB);   a rheology modifier;   a network former;   a solvent;   a viscosity enhancing agent; and   a saturated polyglycolized glyceride,   wherein the formulation does not include hydroxyethylcellulose (HEC).   
     
     
         59 . The formulation of  claim 58 , wherein the methylphenidate is present in the formulation at about 5 wt % to about 30 wt % relative to the total weight of the formulation. 
     
     
         60 . The formulation of  claim 58 , wherein the SAIB is present in the formulation at about 30 wt % to about 45 wt % relative to the total weight of the formulation. 
     
     
         61 . The formulation of  claim 58 , wherein the rheology modifier comprises isopropyl myristate (IPM). 
     
     
         62 . The formulation of  claim 61 , wherein the IPM is present in the formulation at about 2 wt % to about 15 wt % relative to the total weight of the formulation. 
     
     
         63 . The formulation of  claim 58 , wherein the network former comprises cellulose acetate butyrate (CAB). 
     
     
         64 . The formulation of  claim 63 , wherein the CAB is present in the formulation at about 2 wt % to about 10 wt % relative to the total weight of the formulation. 
     
     
         65 . The formulation of  claim 58 , wherein the solvent comprises triacetin. 
     
     
         66 . The formulation of  claim 65 , wherein the triacetin is present in the formulation at about 15 wt % to about 40 wt % relative to the total weight of the formulation. 
     
     
         67 . The formulation of  claim 58 , wherein the viscosity enhancing agent comprises a stiffening agent. 
     
     
         68 . The formulation of  claim 58 , wherein the viscosity enhancing agent comprises silicon dioxide (SiO 2 ). 
     
     
         69 . The formulation of  claim 68 , wherein the SiO 2  is present in the formulation at about 0.1 wt % to about 2 wt % relative to the total weight of the formulation. 
     
     
         70 . The formulation of  claim 58 , wherein the saturated polyglycolized glyceride is present in the formulation at about 0.01 wt % to about 5 wt % relative to the total weight of the formulation. 
     
     
         71 . A formulation comprising:
 methylphenidate;   sucrose acetate isobutyrate (SAIB);   a rheology modifier;   a network former;   a solvent;   a viscosity enhancing agent;   a saturated polyglycolized glyceride; and   a stabilizer.   
     
     
         72 . The formulation of  claim 71 , wherein the methylphenidate is present in the formulation at about 5 wt % to about 30 wt % relative to the total weight of the formulation. 
     
     
         73 . The formulation of  claim 71 , wherein the SAIB is present in the formulation at about 30 wt % to about 45 wt % relative to the total weight of the formulation. 
     
     
         74 . The formulation of  claim 71 , wherein the rheology modifier comprises isopropyl myristate (IPM). 
     
     
         75 . The formulation of  claim 74 , wherein the IPM is present in the formulation at about 2 wt % to about 15 wt % relative to the total weight of the formulation. 
     
     
         76 . The formulation of  claim 71 , wherein the network former comprises cellulose acetate butyrate (CAB). 
     
     
         77 . The formulation of  claim 76 , wherein the CAB is present in the formulation at about 2 wt % to about 10 wt % relative to the total weight of the formulation. 
     
     
         78 . The formulation of  claim 71 , wherein the solvent comprises triacetin. 
     
     
         79 . The formulation of  claim 78 , wherein the triacetin is present in the formulation at about 15 wt % to about 40 wt % relative to the total weight of the formulation. 
     
     
         80 . The formulation of  claim 71 , wherein the viscosity enhancing agent comprises a stiffening agent. 
     
     
         81 . The formulation of  claim 71 , wherein the viscosity enhancing agent comprises silicon dioxide (SiO 2 ). 
     
     
         82 . The formulation of  claim 81 , wherein the SiO 2  is present in the formulation at about 0.1 wt % to about 2 wt % relative to the total weight of the formulation. 
     
     
         83 . The formulation of  claim 71 , wherein the saturated polyglycolized glyceride is present in the formulation at about 0.01 wt % to about 5 wt % relative to the total weight of the formulation. 
     
     
         84 . The formulation of  claim 71 , wherein the stabilizer comprises an antioxidant. 
     
     
         85 . The formulation of  claim 84 , wherein the stabilizer comprises at least one compound selected from sodium citrate, ascorbyl palmitate, vitamin A, and propyl gallate, ascorbic acid, vitamin E, sodium bisulfite, butylhydroxyl toluene (BHT), butylhydroxyl acid (BHA), acetylcysteine, monothioglycerol, phenyl-alpha-naphthylamine, lecithin, and ethylenediaminetetraacetic acid (EDTA). 
     
     
         86 . The formulation of  claim 85 , wherein the stabilizer comprises BHT.